Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Development of Dengue Virus Type 3 Vaccine Candidates

Posted Oct 06 2009 5:00pm

Description of Invention:
The disease burden associated with dengue virus infection has increased over the past several decades in the tropical and semi-tropical regions of the world, where over 2 billion people live at risk of dengue infection. Annually, there are an estimated fifty (50) to one hundred (100) million cases of dengue fever, making development of an effective vaccine a priority. In addition, there is a need for a "travelers vaccine" to protect those visiting dengue virus endemic areas, similar in scope to other currently available "travelers vaccines", such as hepatitis A vaccine.

The previously identified delta30 attenuating mutation, created in each dengue virus serotype by the removal of 30 homologous nucleotides from the 3'-UTR, is capable of attenuating wild-type strains of dengue virus type 1 (DEN1), type 4 (DEN4) and to a limited extent type 2 (DEN2). These DEN1delta30 and DEN4delta30 viruses have been shown to be both safe and immunogenic in humans. However, the delta30 mutation failed to have an attenuating effect on dengue virus type 3 (DEN3). To generate DEN3 vaccine candidates with a clearly attenuated phenotype, viruses were produced containing 3'-UTR deletions consisting of extensions of the original delta30 mutation or additional mutations which remove stem-loop structures similar to those removed by delta30. In addition, the entire 3'-UTR of DEN3 was replaced with the 3'-UTR derived from DEN4 and containing the delta30 mutation. Studies in monkeys demonstrated that these newly developed viruses are highly attenuated, yet sufficiently immunogenic to warrant their further development for use as live attenuated vaccine candidates. Such viruses are anticipated to become the DEN3 component of a tetravalent vaccine formulation designed to immunize against all four dengue virus serotypes.

Applications:
Immunization against all four serotypes of Dengue Virus.

Development Status:
Vaccine candidates have been synthesized and preclinical studies have been performed. The vaccine candidates of this invention are slated to enter Phase I clinical trials in the next year.

Inventors:
Stephen S Whitehead (NIAID)
Brian R Murphy (NIAID)
Joseph E Blaney (NIAID)


Patent Status:
HHS, Reference No. E-139-2006/0
US, Application No. 12/376,756 filed 06 Feb 2009
PCT, Application No. PCT/US2007/076004 filed 15 Aug 2007


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The National Institute of Allergy and Infectious Diseases, Laboratory of Infectious Diseases, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these vaccines. Please contact Dr. Brian Murphy at 301-594-1616 or bm25f@nih.gov for more information.


Portfolios:
Infectious Diseases
Infectious Diseases - Diagnostics
Infectious Diseases - Vaccines
Infectious Diseases - Research Materials
Rare Diseases
Neglected Diseases



For Additional Information Please Contact:
Peter Soukas J.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 14,
Rockville, MD 20852-3804
United States
Email: soukasp@mail.nih.gov
Phone: 301-435-4646
Fax: 301-402-0220


Ref No: 1585

Updated: 10/2009

Post a comment
Write a comment:

Related Searches